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Abstract The human homologue of the recently cloned murine 
IL-13 binding protein (IL-13Ral) was cloned from a cDNA 
library derived from the carcinoma cell line CAKI-1. The cloned 
cDNA encodes a 427 amino acid protein with two consensus 
patterns characteristic of the hematopoietic cytokine receptor 
family and a short cytoplasmic tail. The human protein is 74% 
identical to the murine IL-13Ral, and 27% identical to the 
human IL-13Ra2. CHO cells expressing recombinant hlL-
13Ral specifically bind IL-13 (Äd~4 nM) but not IL-4. Co-
expression of the cloned cDNA with that of IL-4Ra resulted in a 
receptor complex that displayed high affinity for IL-13 (Κ^ ~ 30 
pM), and that allowed cross-competition of IL-13 and IL-4. 
Electrophoretic mobility shift assay showed that IL-13 and IL-4 
were able to activate Stat6 in cells expressing both IL-4Roc and 
IL-13Ral, while no activation was observed in cells expressing 
either one or the other alone. 
Key words: IL-13 binding protein; IL-13 signal transduction; 
IL-4 receptor complex 
1. Introduction 
Interleukin-13 (IL-13) is a cytokine secreted by activated T-
lymphocytes which regulates inflammatory and immune re-
sponses [1,2]. It shares several biological activities with IL-4, 
another T-cell derived cytokine, in a variety of cell types such 
as B-cells, monocytes, fibroblasts and endothelial cells [3]. 
The functional redundancy of IL-4 and IL-13 suggested 
very early on that both cytokines probably shared receptor 
components [4-6]. The IL-4 receptor comprises two chains, 
the IL-4Ra and the yc [7-10]. Neither of these two chains 
binds IL-13 [5], but recent reports have shown that IL-4Ra 
contributes to the IL-13 receptor [11-13]. 
Recently, two proteins that bind specifically IL-13 have 
been cloned, one from murine tissue [14] and the other from 
human cells [15]. Since both proteins are most probably re-
sponsible for the initial interaction of IL-13 with the receptor 
complex(es) we propose to call them IL-13Ral and IL-
13Ra2. IL-13Ral and IL-13Rot2 are distantly related (27% 
identity and 46% homology), but both proteins have short 
cytoplasmic domains, and two consensus patterns, four con-
served cysteines in the amino-terminal half of the extra cellu-
lar domain and the WSXWS motif located in the C-terminal 
region of the extra cellular domain, considered signatures of 
the hematopoietic cytokine receptor family (for review see 
[19]). Interestingly, both proteins bind IL-13 with very differ-
ent affinities, Kd~l0 nM and 50 pM for IL-13Rcxl and IL-
13Ra2, respectively. We describe here the cloning of the hu-
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man IL-13Ral, and the pharmacological and functional char-
acterization of the recombinant protein expressed alone or 
with IL-4Rot in stably transfected CHO cells. 
2. Materials and methods 
2.1. Growth factors and cells 
Recombinant ML-13 was produced and purified in our laboratory 
as previously described [2]. Human IL-4 was obtained from Tebu (Le 
Perray en Yvelines, France). 
CAKI-1 cells (ATCC HTB 46), the B9 hybridoma cell line, and 
CHO cells were cultured as described [15]. 
2.2. cDNA library construction, isolation of cDNAs and sequence 
analysis 
Total RNA from B9 hybridoma cells was used to synthesize cDNA 
[2]. A specific DNA fragment of the murine IL-13Rcd was obtained 
by PCR using this cDNA and the following primers: 5'-AGAG-
GAATTACCCCTGGATG-3' (sense) and 5'-TCAAGGAGCTGCT-
GCTTTCTTCA-3' (anti-sense) corresponding to the nucleotides 249-
268 and 1256-1275, respectively, of the mIL-13Rcd sequence de-
scribed by Hilton et al. [14]. 
The PCR product obtained (1027 bp) was purified, labelled (specific 
activity 2.4 X109 dpm^g) using the Random Primers DNA labelling 
kit (BRL), and used as a probe to screen a CAKI-1 cDNA library 
[15]. 
2.3. Binding and biological activity assays 
Binding experiments on transfected CHO cells were performed 
using radiolabelled hIL-13 as described [5]. 
For the electrophoretic mobility shift assay (EMSA), 2X106 CHO 
cells or recombinant cell lines were plated onto 10 cm dishes and 
transfected 24 h later with 6 μg of plasmid DNA. After 48 h, the cells 
were washed and incubated in the presence of hIL-13 or hIL-4 (10 
nM) for 30 min at 37°C, then rinsed twice with cold PBS containing 
0.5 mM EDTA, harvested with a cell scraper in 1.2 ml PBS and finally 
transferred into 1.5 ml microcentrifuge tubes. Cellular extracts were 
prepared as described by Jiang and Eberhardt [16]. Gel shift assays 
were performed as described by Kölher et al. [17] with 10-20 μg of 
proteins and 5 x l 0 4 - l x l 0 5 cpm of the 32P-labelled probe corre-
sponding to the human CE element from the human Ce control region 
[18] (5'-GATCCACTTCCCAAGAACAGA-3', the core sequence is 
underlined). Stat6 containing complexes were confirmed by supershift-
ing with 2 μg of a monoclonal antibody anti-Stat6, M20 (Santa Cruz, 
CA), added to the binding reaction before EMSA. 
3. Results 
3.1. Cloning and sequencing of the human IL-13Ral 
A DNA fragment of the murine IL-13Rocl [14] was derived 
from B9 total RNA and used to screen by hybridization a 
CAKI-1 cDNA library. Homologous sequences were rela-
tively abundant (1/5000). The homologous full length cDNA 
is 3999 bases long, excluding the poly-A tract, and has a long 
3' untranslated region of 2145 bases. A canonical AATAAA 
polyadenylation signal is found at the predicted location. The 
open reading frame between nucleotides 34 and 1851 defines a 
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Fig. 1. Amino acid sequence of human IL-13Ral. The amino acids 
corresponding to the predicted signal peptide are indicated with 
dashes. Potential JV-glycosylation sites (Asn-X-Ser/Thr) are labelled 
with asterisks. Conserved cysteines in the hematopoietic cytokine re-
ceptor family are labelled with solid circles. The WSXWS and 
PXXPXP motifs are boxed. And the transmembrane domain is un-
derlined. The human IL-13Ral cDNA sequence has been submitted 
to the EMBL Data Library (accession number Y09328). 
polypeptide of 427 amino acids. The sequence codes for a 
membrane protein with a putative signal peptide, a single 
membrane-spanning domain and a short cytoplasmic tail 
(Fig. 1). Ten sites for potential N-linked glycosylation are 
located in the extracellular region. Importantly, two consensus 
patterns considered signatures of the hematopoietic cytokine 
receptor family (for review see [19]) are also found, four con-
served cysteines in the amino-terminal half of the extra cellu-
lar domain, and the WSXWS motif located in the C-terminal 
region of the extra cellular domain. Furthermore, a proline-
rich motif (PXXPXP) is located in the cytoplasmic region 
near the transmembrane domain. Alignment studies reveal 
homologies with the murine IL-13Ral (74% identity and 
84% similarity) and to a lesser extent with the human IL-
13Ra2 (27% identity and 51% similarity) and with the human 
IL-5Ra (26% identity and 46% similarity). 
3.2. Expression and characterization of the IL-13 binding 
protein 
CHO cells transfected with the isolated cDNA encoding the 
IL-13Rod showed specific binding of labelled IL-13. Scatch-
ard analysis of the saturation curve showed a single compo-
nent site with a Kd value of 4.5 ±0.5 nM and a maximal 
binding capacity of 2.6 X104 receptors/cell (Fig. 2A). The af-
finity displayed by the recombinant receptor is much lower 
than that displayed by the IL-13Rot2, with a Kd of 57 ±10 
pM [15]. However, when the saturation experiments were per-
formed on CHO cells co-expressing IL-13Rod with IL-4Ra, 
the Scatchard analysis clearly showed the presence of two sites 
for IL-13 (Fig. 2B). One exhibited a dramatic increase in 
affinity (K^: 32 ± 8 pM), and the other had a KA similar to 
the one observed in the cells expressing IL-13Ral alone, 
4.2 ± 1.4 nM. The high affinity binding site was not detected 
if the saturation experiments were performed in the presence 
of a large excess of IL-4 (not shown). No modification in IL-
13 affinity resulted from the co-expression of IL-13Rotl and 
IL-13Roc2 (not shown) and IL-13 did not bind to IL-4Ra, as 
previously described [5]. 
In competition studies, IL-13 was effective in inhibiting the 
labelled IL-13 binding to the cells expressing the IL-13Ral. 
Labelled IL-4 neither bound to the IL-13Rod, nor inhibited 
the binding of labelled IL-13 to this receptor (Fig. 3A). Sev-
eral other cytokines (IL-2, IL-3, IL-5, IL-7, GM-CSF) were 
not able to displace IL-13 binding (not shown). However, 
when IL-13Rocl and IL-4Roc were co-expressed in CHO cells 
a high affinity binding site for IL-13 was reconstituted, as 
shown in Fig. 2B, and this high affinity IL-13 binding was 
fully displaced not only by IL-13 but also by IL-4 (Fig. 3B). 
Co-expression of the IL-13Rcel and IL-4Roc did not change 
the affinity of the IL-4 receptor for IL-4 (not shown) but 
allowed displacement of labelled IL-4 by IL-13 (Fig. 3C). 
These results show that both receptor chains interact in the 
cell membrane to reconstitute a receptor complex that dis-
plays high affinity for IL-13 and that is shared by both IL-
13 and IL-4. 
3.3. Biological activity 
To examine whether IL-13Ral is able to transduce a signal 
to the cell we analyzed the activation of Stat6 because this 
regulator of gene transcription is activated by IL-13 and IL-4 
[17]. Stable transfectants expressing IL-13Ral either alone or 
in combination with IL-4Rce were stimulated with IL-13 or 
IL-4 and the nuclear extracts were analyzed for binding to an 
oligonucleotide probe containing the Ce Stat response element 
from the Ce human control region [18]. The results (Fig. 4) 
showed that no activation was detected in non-transfected 
CHO cells incubated with IL-4 or IL-13. Similar negative 
results were observed on IL-4 or IL-13 stimulation of CHO 
cells expressing either IL-4Rcx or IL-13Ral. However, in 
CHO cells expressing both chains, IL-4Roc and IL-13Ral, 
stimulation with IL-4 or IL-13 clearly resulted in a binding 
activity to the oligonucleotide probe in the nuclear extracts. 
The presence of Stat6 in the complexes was confirmed by 
supershifting experiments as described in Section 2 (not 
shown). 
4. Discussion 
We describe here the cloning and characterization of the 
human IL-13Rcd. The protein, homologous to the IL-13 
binding protein recently cloned from murine tissue (IL-
13Rod) [14], recognizes IL-13 with much lower affinity than 
the other IL-13 binding protein cloned from human cells (IL-
13Ra2) [15]. IL-13 binding to CHO cells expressing hlL-
13Ral cannot be displaced by IL-4. Co-expression of IL-
4Ra with IL-13Ral resulted in the reconstitution of a recep-
tor complex that bound IL-13 with higher affinity than the IL-
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Fig. 2. Characterization of the recombinant IL-13Ral expressed in 
CHO cells. Scatchard analysis of the [125I]IL-13 saturation curve 
with cells expressing (A) IL-13Ral, which indicated the presence of 
~ 26 000 sites/cell with a Kd of 4.5 ±0.5 nM and (B) IL-13Rotl and 
IL-4Ra, which indicated the presence of ~4000 sites/cell with a Kd 
of 32 ± 8 pM and of ~ 20 000 sites/cell with a Kd of 4.2 ± 1.4 nM. 
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13 and IL-4 as previously described for the murine IL-13Rocl 
[14]. The experiments of activation of Stat6, as assayed by its 
property to bind to a specific sequence from the Ce promoter, 
complete and extend the binding results. IL-13Roel by itself is 
not capable of transducing a signal either for IL-13 or for IL-
4, but when co-expressed with IL-4Rce it is capable of recon-
stituting a receptor complex that is able to transduce a signal 
for both cytokines. It should be noted that CHO cells expres-
sing only IL-4Ra do not respond to IL-4 as measured by 
Stat6 activation. Since CHO cells do not express 7c (unpub-
lished results), the results are in line with previous reports that 
indicated the need for 7c for the reconstitution of a functional 
IL-4 receptor [20]. The activation of Stat6 by IL-4 in cells co-
expressing IL-4Ra and IL-13Ral clearly show that IL-13Rocl 
can replace ye for the reconstitution of an active IL-4 recep-
tor. The fact that IL-13Ral can replace yc for the reconstitu-
tion of an active IL-4 receptor explains, as previously sug-
gested [6], the conflicting reports describing the need for yc 
for an active IL-4 receptor [9,20], and the description of active 
IL-4 receptors in the absence of yc [21,22]. Since the cytoplas-
mic domain of IL-13Ral is 26 amino acids shorter than that 
of yc we are currently investigating whether IL-13Ral contri-
butes to the recruitment of Jak3, as described for yc [23], and/ 
or to other signaling events as recently suggested [24]. In this 
context, it is important to emphasize the presence in the IL-
13Rod of a proline-rich motif located in the cytoplasmic re-
gion near the transmembrane domain suggesting that IL-
13Ral can associate with some kinases of the Jak family 
[25]. Together, these results show that IL-13Rod and IL-
4Roc are sufficient to reconstitute a functional receptor for 
IL-13 and IL-4, and they do not exclude the possibility that 
other protein(s) may be associated in some cell types with the 
natural IL-4/IL-13 receptor complex as recently described for 
yc [24,26]. Two recent reports describe the homodimerization 
of IL-4R« and, as a result, the intracellular signaling that 
finally leads to Stat6 activation. In both reports chimeric re-
ceptors were used in which the cytoplasmic and transmem-
brane domains of IL-4Roc were fused to the extracellular do-
main of the erythropoietin receptor [27] and yc [28], and 
dimerization was induced either with erythropoietin or with 
a monoclonal antibody. The apparent contradiction of these 
reports with our observation that CHO cells expressing IL-
4Roc alone do not respond to IL-4 may indicate that if two 
IL-4Ra cytoplasmic domains are brought together they are 
able to transduce a signal to the cell, but that IL-4 does not 
Fig. 3. Cross-competition of IL-13 and IL-4 on CHO cells expres-
sing IL-13Ral alone or with IL-4Ra. A: Displacement of labelled 
IL-13 to cells expressing IL-13Rcd by IL-13 (20 nM) and IL-4 (20 
nM). B: Displacement of labelled IL-13 by IL-13 (20 nM) and IL-4 
(20 nM) on cells expressing IL-13Ral and IL-4Ra. C: Displace-
ment of labelled IL-4 by IL-13 (20 nM) and IL-4 (20 nM) on cells 
expressing IL-13Rocl and IL-4Ra. 
Fig. 4. Signal transduction of IL-13 and IL-4 in CHO cells expres-
sing IL-13Ral alone or with IL-4Ra. The different cell lines, CHO, 
CHO expresssing IL-4Ra (CHO-4), IL-13Ral (CHO-13), and IL-
4Ra and IL-13Ral (CHO-4-13) were incubated in the absence (c) 
or in the presence of 5 nM of IL-4 (4) or IL-13 (13) as indicated 
and then the nuclear extracts were analyzed for Stat6 activation as 
described in Section 2. 
induce dimerization of natural IL-4Ra. In line with this hy-
pothesis are the results of Hoffman et al. who showed that IL-
4 forms a 1:1 complex with the soluble portion of IL-4Ra 
[29]. Alternatively, the dimerization and activation of IL-4Ra 
by IL-4 may depend on the density of the receptor in the cell 
membrane, and/or on the presence of other subunit(s) of the 
receptor complex that are absent in CHO cells. 
In conclusion, our results demonstrate that IL-13Rod and 
IL-4Ra in the absence of yc are sufficient for the reconstitu-
tion of an active IL-13 and IL-4 receptor. The availability of 
the human IL-13Ral and IL-4Ra should allow the design of 
experiments to better assess the stoichiometry and the role 
played by each protein, and the relationship with yc and hu-
man IL-13Ra2, in the functional IL-4/IL-13 receptor com-
plex. 
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